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ABSTRACT
Objectives: Model-based cost-effectiveness analyses support decision-
making. To augment model credibility, evaluation via comparison to inde-
pendent, empirical studies is recommended.
Methods: We developed a structured reporting format for model evalua-
tion and conducted a structured literature review to characterize current
model evaluation recommendations and practices. As an illustration, we
applied the reporting format to evaluate a microsimulation of human
papillomavirus and cervical cancer. The model’s outputs and uncertainty
ranges were compared with multiple outcomes from a study of long-term
progression from high-grade precancer (cervical intraepithelial neoplasia
[CIN]) to cancer. Outcomes included 5 to 30-year cumulative cancer risk
among women with and without appropriate CIN treatment. Consistency
was measured by model ranges overlapping study conﬁdence intervals.
Results: The structured reporting format included: matching baseline
characteristics and follow-up, reporting model and study uncertainty, and
stating metrics of consistency for model and study results. Structured
searches yielded 2963 articles with 67 meeting inclusion criteria and found
variation in how current model evaluations are reported. Evaluation of the
cervical cancer microsimulation, reported using the proposed format,
showed a modeled cumulative risk of invasive cancer for inadequately
treated women of 39.6% (30.9–49.7) at 30 years, compared with the
study: 37.5% (28.4–48.3). For appropriately treated women, modeled
risks were 1.0% (0.7–1.3) at 30 years, study: 1.5% (0.4–3.3).
Conclusions: To support external and projective validity, cost-
effectiveness models should be iteratively evaluated as new studies become
available, with reporting standardized to facilitate assessment. Such evalu-
ations are particularly relevant for models used to conduct comparative
effectiveness analyses.
Keywords: cancer, cost-effectiveness, methods, simulation model,
validation.
Introduction
Decision-makers must choose among policies in the face of con-
siderable uncertainty about their future beneﬁts and costs.
Although empirical studies provide information on speciﬁc inter-
ventions, they often report intermediate outcomes and assess a
limited number of strategies. Delaying a decision while waiting
for optimal data on long-term outcomes may not be feasible.
Decision-analytic computer models—applied in cost-
effectiveness analyses—can provide valuable insights to guide
interim decision-making. By synthesizing available information
and formally considering uncertainty, models extrapolate short-
term study results to project long-term outcomes of different
policy choices [1–3].
For policymakers to incorporate modeling into their deci-
sions, models must be transparent and credible. It is therefore
important to appreciate both the beneﬁts and limitations of
decision models. Though they incorporate the best available data
and science, models are inherently simpliﬁed representations of
the real world. As such, inaccuracies in their predictions can
result when the modeled outcomes of a policy depend on features
that have been simpliﬁed. To promote transparency and credibil-
ity, standardization of methods (e.g., using a “reference case”)
and model quality assessment have been advocated, especially
because models are incorporated into comparative effectiveness
and guidelines development processes [3,4]. To further enhance
transparency and credibility, comparison of model-projected
outputs to outcomes from independent, empirical studies—
termed “model evaluation”—is an important undertaking.
Further, because policy recommendations incorporating model-
derived guidance are used long after the initial model-based
analyses, continued, iterative evaluation of models is warranted.
We developed a structured reporting format for model evalu-
ation and undertook a literature review of model evaluation as
currently used in medicine and public health. The review showed
that although model evaluation is recommended in guidelines
and review articles, more detailed guidance regarding how best
to undertake such an evaluation is limited. We also reviewed
published applications of model evaluation as currently prac-
ticed, ﬁnding a wide range of methods and reporting formats.
Such heterogeneity limits comparisons and hinders efforts to
include results from multiple studies in comparative effectiveness
analyses and policy formulation.
To illustrate the use of the reporting format, we applied it to
our ongoing evaluation of an empirically calibrated human pap-
illomavirus (HPV) and cervical cancer microsimulation model
used for policy analyses in the United States [5–8]. With policy
debates surrounding prevention of HPV infection and cervical
cancer evolving rapidly, iterative model evaluation is particularly
appropriate.
Methods
Deﬁnitions
Our study focuses on external model evaluation, which refers
here to external consistency or projective validity. Model evalu-
ation is deﬁned as the comparison—without adjustment of the
model’s parameters—of the model’s outcomes to outcomes from
empirical study data not used in the model’s construction,
parameterization, or calibration [3,9]. In contrast, calibration is
deﬁned as the process of determining the values of unobservable
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parameters by constraining model output to replicate observed
data [10]—explicitly modifying model parameters to match such
data.
Recommended Reporting of External Model Evaluation
Recommendations are summarized in a structured reporting
format for model evaluation in Table 1. When there are multiple
studies that a model’s output could be compared with, a state-
ment describing the decision rule by which studies were selected
should be included along with relevant information about the
studies’ designs and populations. A statement characterizing the
match between the modeled population, and baseline study char-
acteristics and protocol should be included. Model outputs may
differ from external studies both because of the model’s param-
eters and structure, and because of differences in the baseline
characteristics of the population modeled or the modeled
follow-up protocol. By matching baseline characteristics and
follow-up, evaluation can focus on key differences (i.e., param-
eters and structure) relevant for policy analyses. Outcomes and
associated uncertainty bounds should be reported for both the
study and the model. The use of multiple outcomes from multiple
studies, if available, can add further credibility. Model and study
outcomes should be compared using a metric of consistency that
is explicitly stated. Assessment of similarities and differences
between modeled and study outcomes should be assessed along
with their potential impact on long-term policy-relevant out-
comes. In situations where model evaluation is reported as part
of a policy analysis or when the model is compared with large
numbers of studies [11,12], space constraints may preclude
reporting all information in the article itself. A supplemental Web
appendix to describe fully the model’s comparison with each
study should be included.
Structured Literature Review
We characterized existing guidance for and practice of model
evaluation in the context of model-based cost-effectiveness analy-
ses, performing a structured literature review. The goals of the
review were: 1) to synthesize any prior guidance on model evalu-
ation and report dissenting opinions in the literature; and 2) to
document whether guidance, in the absence of reporting stan-
dards, is being followed by simulation modelers. Our searches of
MEDLINE (1966–2008) used keyword combinations including:
“model,” “validation,” “evaluation,” “external,” “simulation,”
“policy,” “cost,” “effectiveness,” “utility,” “decision,” “ana-
lytic,” “health,” and “economic.” Detailed descriptions of the
speciﬁc searches performed are included in Appendix SA
and can be found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i5_Goldhaber-Fiebert.asp. The bibli-
ographies of resulting articles were also scanned for additional
sources.
We limited inclusion of articles returned by our search pro-
cedure to those that are in English, about human health, and
simulated disease processes with discrete event simulation,
Markov, semi-Markov, microsimulation, or differential equation
models. Additionally, articles were also required to address
external model evaluation—the comparison of the model to
empirical studies not used in the model’s construction or cali-
bration [3,9].
The search procedure is presented in Figure 1. Searches
yielded 2963 articles. Title/abstract reviews resulted in 238
selected for full text review. Among these 238 articles, 67
articles (23 reviews/guidelines and 44 applications) met all
inclusion criteria. The remaining articles were excluded because
they only cited prior evaluation (49 articles); only mentioned
the need for external evaluation (30 articles); or for other less
common reasons such as only assessing internal consistency
(i.e., comparing model outputs to data used in its construction),
or modeling animal diseases.
Results
Current Guidance
In the 23 review and guidelines articles referencing external
model evaluation, a small minority framed model evaluation as a
validation exercise concerned with the “falsiﬁcation” of the
model [13,14]. The majority—especially more recent reviews and
Table 1 Structured model evaluation report
Reporting category Detailed information
Empirical study description Rationale for selection (e.g., large, high-quality, only available)
Design (e.g., randomized controlled trial, observational cohort)
Relevant details (e.g., sample size, year conducted, geographical location)
Explicit statement that the study was not used to construct the model
Baseline characteristics Characteristics used to match the modeled and actual study populations (e.g., ages and, potentially, birth cohorts, risk factors)
Statement if study does not provide sufﬁcient information such as the distribution of baseline characteristics or, more likely, the
co-occurrence of risk factors
Statement if the model does not incorporate certain risk factors thought to be inﬂuential in the studied outcome
Statement that the model does not explicitly match on baseline characteristics as both the model and study are generally
representative of similar populations
Study protocol How subjects are identiﬁed, enrolled, and, potentially, assigned to exposure or treatment
Follow-up and variability of follow-up
Loss to follow-up
How study measurements are performed (tests used)
Statement if study does not provide sufﬁcient data on variability and loss to follow-up and any assumptions used
Study outcomes Point estimates
Measures of uncertainty
Model outcomes Point estimates
Measures of uncertainty
How model uncertainty was generated (e.g., probabilistic sensitivity analysis, empirical calibration)
Model consistency What metrics of consistency were used
How model and study outcomes meet these metrics
Assessment of robustness and/or possible reasons for differences
Likely impact on policy conclusions
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guidelines—view model evaluation in terms of a cumulative
process that adds to the general credibility of results through the
comparison of the model to independent data not used in its
construction [4,15–34].
Although the rationale for comparing models and data, and
the types of comparisons made are comprehensive, relatively few
articles [15,16,29] provide best practices for performing model
evaluations. The following general practices, included in our
structured reporting format, were consistent with the 23 reviews:
1) simulation of the same distribution of baseline characteristics
and study protocol when generating model outcomes; 2) com-
parison to multiple studies; 3) comparison to multiple outcome
types; and 4) incorporation of model and study uncertainty in the
comparison of outcomes. Notably, few articles mentioned crite-
ria for assessing the consistency of model-predicted outcomes
and study results. Although some suggested the use of statistical
comparisons, others focused on assessing consistency based on
the impact on policy conclusions [29,33], presumably by updat-
ing the model and its parameters, and reassessing policies recom-
mended for the decision problem.
Current Practice
We assessed 44 application articles identiﬁed via the literature
review, evaluating whether the general recommendations con-
tained in guidelines and review articles were in common practice
[6,11,12,35–75]. Of these 44, 25% compared results only to
randomized controlled trials, 66% compared results only to
observation studies and population registries, and 9% compared
results to both types of studies.
We found that 84% (37 of 44) of articles reported some
baseline characteristic (e.g., age distribution, birth year, starting
risk level, etc.) and that 66% (29 of 44) of articles explicitly
reported matching the study protocol. For comparisons to
population-representative observational studies (e.g., statistics
from comprehensive cancer registries), baseline characteristics
and surveillance may have been assumed to be implicitly similar
and, hence, not reported. Consequently, we considered reporting
of baseline characteristics and protocol for those articles making
comparisons to randomized controlled trials. In this subgroup,
we found that 73% reported both matching baseline character-
istics and protocol, whereas 53% of comparisons to observa-
tional studies reported both baseline and protocol.
We found that 55% (24 of 44) of articles compared model
outcomes to outcomes from multiple studies, though this likely
underestimates the true percentage because evaluations of the
same model could have been published in several, separate
articles. Furthermore, even when modelers may have wished to
compare with multiple studies, lack of data may have impeded
them. Models and studies were compared based on multiple
outcomes in 93% (41 of 44) of articles.
Figure 1 The search procedures used to identify
review and guidelines articles as well as application
articles dealing with external model evaluation in
the context of disease simulation models of human
health.
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Application articles used a wide variety of assessment metrics
in making their comparisons of study and model outcomes.
Comparisons included: 1) the relative or absolute difference in
model and study point estimates; 2) the overlap of model out-
comes with study uncertainty ranges; and 3) formal statistical
tests where a P-value greater than 0.05 or other critical level
implied no detectable statistical difference. Less than half of the
articles, 43% (19 of 44), reported on uncertainty when compar-
ing model and study outcomes. Reporting uncertainty took a
variety of forms, including the use of conﬁdence intervals, or
ranges of study and modeled outcomes, or the use of statistical
tests. Only 11% (5 of 44) of the articles provided estimates of
uncertainty about modeled outcomes, with most comparing the
point estimates of the model to the study results.
Example Application: US Cervical Cancer Model
Context and model. Cervical cancer is caused by infection with
high-risk types of HPV [76]. Systematic, high-quality screening
programs can prevent cervical cancer [77–80]. With the avail-
ability of alternative screening technologies [81] and two pro-
phylactic HPV vaccines targeting common oncogenic HPV
subtypes [82], important policy questions are raised.
Previously, we constructed an individual-based simulation
model of the natural history of HPV and cervical cancer. The
model was empirically calibrated to multiple studies. Empirical
calibration indentiﬁed multiple sets of model inputs with which
to generate uncertainty ranges around modeled policy outcomes
[6]. Brieﬂy, the microsimulation tracks individual females from
age 9. Each month, there is an age-speciﬁc risk of infection with
HPV, with HPV stratiﬁed by risk type. Infections can be cleared,
potentially leading to type-speciﬁc immunity. Infections can also
persist, potentially causing cervical intraepithelial neoplasia
(CIN). CIN is classiﬁed as low grade (CIN1) or medium to high
grade (CIN2,3). For women who do not clear their infections,
productive high-risk infection accompanying persistent CIN2,3
can progress to invasive cervical cancer. All women face a
monthly age-speciﬁc risk of death from other causes, and women
with invasive cancer face an additional cancer stage-speciﬁc mor-
tality risk.
Prior use and model evaluation. The model has been used in
policy analyses [7,8]. As the model was built and calibrated in the
absence of interventions (i.e., a natural history model), we
focused our iterative external model evaluation on the addition
of screening and treatment to prevent cervical cancer, speciﬁcally
examining CIN2,3 (high-grade CIN), which is particularly
important as it is often the primary threshold for treatment and
has highly uncertain transition rates to invasive cancer. Previ-
ously, we compared the model to studies of the overall impact of
screening and treatment of high-grade precancer on population
outcomes, such as cancer incidence reduction, ﬁnding reasonable
consistency [6]. Subsequently, we compared the model to studies
of the relationship between cancer and prior frequency of screen-
ing and to those that directly tested the ability of screening that
included HPV deoxyribonucleic acid (DNA) testing to detect
prevalent and incident high-grade CIN [5], again ﬁnding reason-
able consistency.
Current external model evaluation. The details of the current
external model evaluation are presented in Table 2, following our
structured reporting format. The current evaluation involved a
comparison of the model to a unique, retrospective cohort study
of the cumulative risk of cervical cancer for women with high-
grade CIN who were either adequately or inadequately treated
over 30 years of follow-up [83]. To simulate the study, baseline
data on women’s age group and birth cohort as well as cohort-
speciﬁc New Zealand life tables [84] were used. Cumulative risk
of cervical cancer at 5, 10, 20, and 30 years post-enrollment were
noted for the two groups (adequate and inadequate treatment).
Model uncertainty depended on parameter uncertainty identiﬁed
with the model’s original empirical calibration [6,7]. Consistency
was assessed based on overlap of the study’s 95% conﬁdence
intervals and model ranges. The modeled outcomes were largely
consistent with the study at all time points with substantial
overlap between study conﬁdence intervals and model ranges.
Further details on the current step of the external model
evaluation are available in Appendix SB at: http://www.ispor.
org/Publications/value/ViHsupplementary/ViH13i5_Goldhaber-
Fiebert.asp.
Conclusions
Model evaluation—comparing study and model-based
outcomes—is an important way to enhance transparency and
credibility for models used in policy analyses. In order for models
to inform comparative effectiveness analyses and guidelines
setting efforts, credibility must be established for the models
used. Model evaluation plays an important role in this endeavor.
Our structured literature review of 67 articles revealed strong
support for model evaluation and some commonalities in
approach. We also found a degree of heterogeneity in how results
of model evaluations are reported. To promote transparency and
credibility in model evaluation, we developed a structured
reporting format and demonstrated its utility by applying it to an
iterative assessment of a previously published microsimulation of
HPV and cervical cancer.
Our ﬁndings illustrate the value of a concise reporting format
such as the one we suggest in iterative model evaluations. Given
the limited space available in peer-reviewed publications, identi-
fying and reporting key details of model evaluations facilitate
transparency for readers. The use of such a reporting format in
conjunction with longer Web appendixes enables both standard-
ized reporting and full, critical assessment. In our example, the
suggested reporting format conveys both overall consistency
between the HPV and cervical cancer model and the empirical
study, and summarizes the manner in which the model evaluation
was conducted. An important job for analysts is to continue to
assess their models in comparison to new studies as they are
published. Our model’s credibility is built gradually through
iterative comparison to and consistency with empirical studies as
they become available. Finally, though studies may comment on
different populations from those represented by the original
model, analysts can still exploit both similarities and differences
to learn about their models, determining parameter changes
needed to equalize baseline population characteristics and then
comparing model and study outcomes using similar follow-up
protocols. In our comparison of a US model to a study from New
Zealand, we were able to make reasonable comparisons, adjust-
ing for background mortality and the age distribution of high-
grade precancer.
Our suggested reporting format and structured literature
review have several limitations. First, our literature review uses
multiple keyword searches in MEDLINE combined with scans of
article bibliographies and does not include a full systematic
review of other databases such as EMBASE, the use of Medical
Subject Heading terms, or searches outside of the medicine and
public health domains. Our search results do, however, identify
application articles covering a broad range of journals, years,
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diseases, and research groups. Second, although our literature
review ﬁnds heterogeneity in how model evaluations are
reported, we cannot comment on the reasons for these differ-
ences. For example, although our review ﬁnds that less than half
of application articles report uncertainty, we cannot distinguish
simple lack of availability from decisions not to include such
information. Our suggested reporting format elicits this type of
information explicitly.
Our study highlights a general methodological issue—how to
appropriately describe consistency. Although some view model
evaluation in terms of formal “validation” through attempts at
“falsiﬁcation,” the general consensus is that repeated compari-
sons in which model and study outcomes are consistent with one
another add to the credibility of model-projected long-term
health and economic outcomes. In light of this, we recommend a
description of consistency that highlights both model and study
uncertainty, and comments on their similarity in reference to
policy-relevant outcomes. One example of such an approach
would be to report the study and model point estimates, and the
degree of overlap between study conﬁdence intervals and model
uncertainty ranges.
An important question raised in the context of model evalu-
ation is what to do when modeled outcomes are inconsistent with
study outcomes. As the model represents the synthesis of avail-
able data and expertise, inconsistency represents an opportunity
to understand why there are differences and improve the model.
One potential reason for inconsistency is a lack of sufﬁcient detail
reported in the real-world studies used in the model evaluation.
For example, without individual-level data from the empirical
study, the co-occurrence of baseline characteristics and their rela-
tionship to patterns of follow-up are difﬁcult to determine. It is
unclear whether and how much bias is introduced when simu-
lating such studies without this detail, an area meriting further
study. Therefore, inconsistency with respect to a study should not
immediately result in discarding the model or its ﬁndings. Nev-
ertheless, caution should be used in applying the model in the
domain that the study comments upon. For example, if the study
elaborates the effect of a particular drug on a particular pathway
or intermediate outcome, then modeled long-term outcomes
based on this drug, pathway, or intermediate outcomes should be
further critically examined. When possible, comparisons should
be made to other studies with results relevant in that area. The
Table 2 Cervical cancer application of the structured reporting format
Reporting category Detailed information
Empirical study description The study provides external model evaluation of the model’s progression component for high-grade CIN (CIN3) to invasive
cervical cancer.
The study used is a unique, retrospective cohort study of women in New Zealand of adequately and inadequately treated CIN3
over a 30-year period published by McCredie and colleagues [83]. Model evaluation focuses on two groups of women from
the study: 1) 92 women with treatment deemed inadequate who had only a punch or wedge biopsy; and 2) 299 women with
treatment deemed adequate.
The study was not used in the construction, parameterization, or calibration of the model.
Baseline characteristics Model and study were matched on baseline age group and birth cohort data in which cohort-speciﬁc New Zealand life tables
[84] were used.All women in the study and model had high-grade CIN at baseline.
Other potentially inﬂuential risk factors including subtype of HPV infection and history of prior infections were unavailable for
matching.
Study protocol The study involved initial treatment of high-grade CIN for some of the participants.All participants were then followed for up to
30 years with cumulative incidence of invasive cancer reported at 5, 10, 20, and 30 years.
In the model-simulated study, all women are followed for 30 years as the study did not detail loss to follow-up.
Study outcomes Inadequate treatment for high-grade CIN, cumulative cancer incidence:
5 years: 17.4% (95% CI 11.1–26.9)
10 years: 26.2% (95% CI 18.4–36.5)
20 years: 34.0% (95% CI 25.2–44.7)
30 years: 37.5% (95% CI 28.4–48.3)
Adequate treatment for high-grade CIN, cumulative cancer incidence:
5 years: 0.0%
10 years: 0.3% (95% CI 0.1–2.4)
20 years: 1.5% (95% CI 0.4–3.3)
30 years: 1.5% (95% CI 0.4–3.3)
Model outcomes Inadequate treatment for high-grade CIN, cumulative cancer incidence:
5 years: 15.5% (95% CI 12.2–19.4)
10 years: 27.8% (95% CI 22.2–34.5)
20 years: 37.5% (95% CI 29.7–46.8)
30 years: 39.6% (95% CI 30.9–49.7)
Adequate treatment for high-grade CIN, cumulative cancer incidence:
5 years: 0.0%
10 years: 0.1% (95% CI 0.1–0.2)
20 years: 0.6% (95% CI 0.4–0.7)
30 years: 1.0% (95% CI 0.7–1.3)
The study protocol was simulated multiple times using the parameter uncertainty derived from the model’s previous empirical
calibration to generate the range of uncertainty around the simulated cumulative risk estimates.
Model consistency Consistency was assessed based on overlap of the study’s 95% CI and model ranges.
Point estimates for adequately treated women differed by 0.5% at 30 years with at least 90% of model parameter sets consistent
with study CIs at all time points. Point estimates for inadequately treated women differed by no more than 3.4% across the
30-year period with at least 80% of model parameter sets consistent with study CIs.
Assessment of robustness involved the effects of all-cause death rates used; regression rates from high-grade CIN to no CIN;
and the inﬂuence of prior infections and immunity. Results remained consistent with the model for death rates, and prior
infections and immunity, suggesting that current high-grade CIN strongly determined future cancer risk and survival.
Regression rates from high-grade CIN were highly inﬂuential.
Although our policy model used rates of high-grade CIN progression and regression calibrated to prevalence data, the current
model evaluation supports the credibility of the modeled reduction in cancer risk and subsequent survival gain from adequate
treatment for screen-detected and diagnosed high-grade CIN.
CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
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primary goal should be to understand the mechanism and mag-
nitude of divergence and its likely impact on policy conclusions,
based on model-projected outcomes.
Model evaluation is an important and feasible part of model-
based cost-effectiveness analyses for many diseases and policy
areas. We anticipate expansion in the use of model-based analy-
ses as interest in comparative effectiveness grows. As model-
based analyses increasingly incorporate methodological best
practices, there is optimism that decision-makers will further
utilize model-projected results. Improving the manner in which
models and their analytic approaches are disseminated will aid in
this regard. To augment the transparency and credibility of long-
term, model-projected costs and beneﬁts, iterative assessment of
a model’s consistency with external data from published studies
should be undertaken when possible and reported with sufﬁcient
information for others to assess.
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this article:
Appendix SA. Structured Review, queries and resulting items.
Appendix SB. External Model Evaluation of the HPV/Cervical Cancer
Model, detailed description of procedures and results for the iterative of
assessment of the HPV/Cervical Cancer microstimulation model in com-
parison to a long-term longitudinal study.
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